2342 — TransGenic Balance Sheet
0.000.00%
- ¥5bn
- ¥5bn
- ¥13bn
- 30
- 55
- 49
- 40
Annual balance sheet for TransGenic, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3,030 | 4,624 | 3,459 | 2,478 | 2,555 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,138 | 893 | 1,076 | 1,336 | 1,212 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,812 | 7,710 | 7,562 | 6,550 | 6,699 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,125 | 1,993 | 1,992 | 2,142 | 2,055 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 8,919 | 10,441 | 10,673 | 9,811 | 9,586 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,165 | 2,659 | 2,744 | 2,434 | 3,272 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 4,002 | 3,908 | 4,655 | 3,917 | 4,824 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 4,916 | 6,533 | 6,018 | 5,894 | 4,763 |
| Total Liabilities & Shareholders' Equity | 8,919 | 10,441 | 10,673 | 9,811 | 9,586 |
| Total Common Shares Outstanding |